KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Work In Process (2017 - 2023)

Biolife Solutions (BLFS) has disclosed Work In Process for 8 consecutive years, with $6.9 million as the latest value for Q1 2023.

  • On a quarterly basis, Work In Process rose 38.54% to $6.9 million in Q1 2023 year-over-year; TTM through Mar 2023 was $6.9 million, a 38.54% increase, with the full-year FY2022 number at $5.7 million, up 13.26% from a year prior.
  • Work In Process was $6.9 million for Q1 2023 at Biolife Solutions, up from $5.7 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.9 million in Q1 2023 to a low of $275000.0 in Q2 2019.
  • A 5-year average of $3.3 million and a median of $3.2 million in 2020 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: plummeted 50.54% in 2019, then skyrocketed 510.18% in 2020.
  • Biolife Solutions' Work In Process stood at $1.9 million in 2019, then rose by 5.8% to $2.0 million in 2020, then soared by 150.0% to $5.0 million in 2021, then rose by 13.26% to $5.7 million in 2022, then rose by 22.08% to $6.9 million in 2023.
  • Per Business Quant, the three most recent readings for BLFS's Work In Process are $6.9 million (Q1 2023), $5.7 million (Q4 2022), and $5.5 million (Q3 2022).